Oncobiologics, Inc. Form 3/A
December 22, 2016

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement Oncobiologics, Inc. [ONS] KENYON LAWRENCE A (Month/Day/Year) 05/12/2016 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) C/O ONCOBIOLOGICS, 05/12/2016 (Check all applicable) INC., 7 CLARKE DRIVE (Street) 6. Individual or Joint/Group 10% Owner Director _X__ Officer Other Filing(Check Applicable Line) (give title below) (specify below) _X_ Form filed by One Reporting CFO and Secretary Person CRANBURY, Â NJÂ 08521 Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) Â 43,478 (2) (3) Restricted Stock Units (1) D Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
		Title	Security	Direct (D)		

Edgar Filing: Oncobiologics, Inc. - Form 3/A

Date Expiration Amount or or Indirect
Exercisable Date Number of (I)
Shares (Instr. 5)

Reporting Owners

Reporting Owner Name / Address	Relationships				
•	Director	10% Owner	Officer	Other	
KENYON LAWRENCE A					
C/O ONCOBIOLOGICS, INC.	â	Â	CFO and Secretary	â	
7 CLARKE DRIVE	Α	А	Secretary	A	
CRANBURY. NJ 08521					

Signatures

/s/ Lawrence A.
Kenyon

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Granted pursuant to the Issuer's 2015 Equity Incentive Plan.
- (2) Each restricted stock unit ("RSU") represents the right to receive, at settlement, one (1) share of the Issuer's common stock.
 - The RSUs are subject to, and to vest must satisfy, both (a) performance-based vesting restrictions (the RSUs will satisfy the performance-based vesting restrictions upon the first to occur of (x) a change of control as defined in the award agreement and (y) the expiration of the 6 month lock-up period following the Issuer's initial public offering, subject to continued service through such event)
- (3) expiration of the 6 month lock-up period following the Issuer's initial public offering, subject to continued service through such event) and (b) time-based vesting restrictions (50% of the RSUs will satisfy the time-based vesting restrictions on each of the third and fourth anniversaries of September 15, 2015, subject to continued service through such dates). In addition, 100% of the RSUs will satisfy the time-based vesting restrictions upon the occurrence of a change of control, subject to continued service through such event.

Â

Remarks:

This Form 3 Amendment is being filed to correct the number of Restricted Stock Units awarded t

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2